ABSTRACT
INTRODUCTION
Neonatal sepsis which refers to a group of physical and laboratory findings in response to invasive infection within the first thirty days of life, 1 is ranked high among the common causes of death in neonates . The incidence of neonatal sepsis in India is 30 per 1000 live-births .2 According to the 2010 WHO statistics, neonatal sepsis accounts for 6% and 7% mortality among children less than five years of age, worldwide and in India respectively. 3 According to National Neonatal Perinatal Database (2002-03), the most common cause of sepsis is Klebsiella pneumoniae, followed by Staphylococcus aureus and Escherchia coli in babies born both within and outside the hospital. Majority of Klebsiella pneumoniae isolates are sensitive to amikacin (114/365, 31.23%), followed by ciprofloxacin (102/381, 26.8%) among inborn babies. Most of the Staphylococcus aureus isolates, were sensitive to vancomycin (11/28, 32.3%) and ciprofloxacin (27/85, 31.8%) in the babies born outside. Most of the E.coli isolates were sensitive to Amikacin, followed by ciprofloxacin.
2 Ciprofloxacin, with concentration dependent killing, is safe 4, 5 and efficacious in sepsis produced by multiresistant organisms. [6] [7] [8] Zelenitsky et al and Kashuba et al have reported a C max /MIC ratio of >10 to be adequate to prevent resistance to this drug. [9] [10] [11] With a lower Cmax in children compared to adults, it was suggested that ciprofloxacin needs to be administered at a dose of 10 mg/kg, eight hourly for resistant organisms. 12 Ciprofloxacin was eliminated slower in neonates (t1/2 2.73 h) compared to the 1 ± 5 year age group (t1/2 1.28 h) 13 . Differences in body weight, hepatic and renal function between preterm and term babies, suggested the need for different dosing regimens for antibiotics like gentamicin. 14 The goal of this study was to determine the incidence of preterm and term neonates who attained therapeutically acceptable Cmax/MIC ratio, at the current recommended dose of 10 mg/kg, twice daily, when treated for sepsis.
MATERIALS AND METHODS
The study was approved by the Institutional Review Board of our hospital. Babies admitted to the Neonatology intensive care unit and who required IV ciprofloxacin were recruited into the study, after obtaining written informed consent from the parent. Only babies above 28 weeks of gestational age and treated with IV ciprofloxacin for minimum of three days were included. And babies who were, critically ill, or in shock were excluded. Baseline details such as age, sex, birth weight, measured biochemical parameters and concurrent medications were recorded.
After specimen was collected for blood culture, ciprofloxacin was initiated in babies having suspected bacterial sepsis. The dose of ciprofloxacin was 10 mg /kg /dose, administered as a 30 minute IV infusion. Sample collection for ciprofloxacin assay was done on Day 3 (dose 5 or dose 6). Both specimens for measuring trough and peak ciprofloxacin concentration were collected into polypropylene eppendorfs. Peak specimens were collected within 10 minutes after discontinuing ciprofloxacin infusion. It was ensured that specimens were not collected from the same limb that ciprofloxacin was administered. Specimens were centrifuged, serum separated and stored at -70° C till analysis.
The blood culture and sensitivity report was followed up for 7 days and MIC was estimated in cases which were culture positive. Clinical and Laboratory Standard Institute's 2011 supplement on "Performance standards for antimicrobial susceptibility, report that an organism is considered to be sensitive, have intermediate sensitivity and resistant to ciprofloxacin if the MIC for ciprofloxacin is <1, 2 and >4, respectively. This criteria for interpreting sensitivity to ciprofloxacin does not hold for gonococci. For babies with sterile blood culture, the above three MIC values were used to calculate Cmax/MIC.
High Performance Liquid Chromatography (HPLC) Assay
The samples were analyzed for ciprofloxacin concentration by high performance liquid chromatography, using Discovery ®HS C18 column (25cm x 4.6mm, 5µm). The mobile phase was 14.5mM phosphate buffer with pH3 (75%) and methanol (25%), at a flow rate of 1ml/minute and detected at 277nm. Samples were extracted by simple protein precipitation using zinc sulphate and methanol, with ornidazole as internal standard. Imprecision calculated as the interday coefficients for the quality control (5µg/ml) was 4.2%. There were no interferences from the medications commonly administered within this population.
RESULTS
A total of 95 neonates were recruited into the study from June 2010 to June 2011. Of which 30 babies were very preterm (28-31 wks), 35 moderately preterm (32-36 wks) and 30 term (37 weeks and above). The mean (SD) ciprofloxacin peak and trough concentrations are reported in table 1.
As seen in table 2, there was poor correlation between both the age and birth weight with ciprofloxacin concentrations in all the three gestational age groups. One way Anova with bonferroni correction showed no significant difference in the trough (p value =0.121) or peak measurements (p value =0.765) between the groups.
Blood culture isolates were positive in 18 babies (19%) and MIC was done for 14 blood culture isolates. The organisms isolated were B. Cepacia (n=6), Klebsiella (n=4), Staphylococcus Aureus (n=2), Enterococcus (n=1), E.coli (n=1) and non fermenting gram negative bacilli (n=1). Five of the strains were sensitive to ciprofloxacin (Staphylococcus Aureus, B. Cepacia, Klebsiella and GFNB), three (Enterococci, B.Cepacia) had intermediate sensitivity and 6 strains (Staphylococcus Aureus, B.Cepacia, Klebsiella.E.coli) were resistant to ciprofloxacin.
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DISCUSSION
Ciprofloxacin serum concentration was not significantly different between babies in the three gestational age groups. The probable reason being that changes with respect to body water, liver and kidney maturation may not affect ciprofloxacin pharmacokinetics in neonates. A detailed pharmacokinetic study is required to explain this, which at the same time may be extremely difficult due to ethical considerations regarding number of blood samples in critically ill neonates.
The trough and peak concentrations (collected within 10 minutes of the end of infusion) of ciprofloxacin measured in term and preterm neonates in this study were higher compared to that in neonates from North India, in whom the mean trough and peak measurements (collected 15 minutes after the end of infusion) ranged from 0.7 to 1.0 μg/ml and from 2.3 to 3.0 μg/ml respectively. 15 Van den Oever, H.L. et al and Bannon, M.J et al also reported ciprofloxacin trough and peak measurements, in the lower range.
13, 16 The increased concentration in peak and trough could be attributed to genetic variability contributing to difference in metabolism and clearance. Blood culture growth was followed up till 7days, as most of the culture reports were positive by about 72 hours. 17, 18 B.Cepacia was the most common organism isolated but the MIC for each strain was different. Since the time point of the incidence of sepsis with this organism was different, the implication was that the source of infection was different.
In neonates with culture positive reports, the C max /MIC was above 10 for sensitive strains but for strains of intermediate sensitivity or resistant to ciprofloxacin the target C max /MIC was not reached. Surprisingly in babies with sterile culture reports, inspite of the higher concentration of ciprofloxacin in our population, Cmax/MIC would be inadequate (ie <10) in more than 25% of patients, if infected with sensitive organisms. And if infected with organisms of intermediate sensitivity only 7.41% of babies would achieve adequate Cmax/MIC. If the organism showed resistance to ciprofloxacin, no baby would achieve an adequate Cmax/MIC. The wide inter-patient variability in trough and peak concentration of ciprofloxacin especially in term babies may be a reason for promoting emergence of resistance even if dosing was based on weight. This is supported by the lack of correlation between birth ISSN: 2250-1177
[105] CODEN (USA): JDDTAO weight and serum ciprofloxacin concentration in neonates. Our neonates may need to be treated with a higher dose to improve Cmax/MIC and to check promotion of further resistance to ciprofloxacin. But to our knowledge more work needs to be done using higher doses and studying their side effects in neonates.
CONCLUSION
The current recommended dose of intravenous ciprofloxacin might be adequate for treating sepsis due to susceptible organisms, in the Indian neonate population. However higher dosing regimens may need to be adopted, after confirming its safety in neonates, when ciprofloxacin is used for organisms with intermediate susceptibility or with resistant organisms.
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